Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a...

Breast cancer (BC) has become the most prevalent malignancy worldwide in recent years. Human epidermal growth factor receptor 2 (HER2) low-expressing tumors account for approximately 60% of BCs in clinical practice, and HER2 low-expression is defined as immunohistochemistry (IHC) 1+ or 2+, along with negative fluorescence in situ hybridization (FISH). Although the efficacy of antibody-drug combinations (ADCs) for the treatment of metastatic HER2 low-expressing BC has been demonstrated, there is still a lack of data on the clinicopathologic characteristics, risk of recurrence, and adjuvant treatment outcomes of early-stage HER2-overexpressing BC compared with non-HER2-overexpressing BC. The objective of this study is to explore whether the clinically validated RecurIndex assay could provide additional prognostic stratification between HER2-low and HER2-zero early-stage BCs in a real-world, single-center cohort.

A retrospective analysis of data from 120 patients diagnosed with pT1-2N1M0 BC who had undergone RecurIndex testing. In order to enhance our comprehension of HER2-negative and HER2-positive tumors, we examined the clinicopathological characteristics, survival outcomes, and the RecurIndex risk model index for BCs categorized by HER2 status.

In our study, there were significantly fewer hormone receptor-positive (HR⁺) patients in the HER2-zero group than in the HER2-low group. Other than that, other clinical characteristics were similar. Local recurrence (LR) and distal recurrence (DR) scores were statistically increased in the HER2-zero group (LR-score: HER2-zero vs. HER2-low group: median 41.3 vs. 39.2, P=0.03; DR-score: median 46.9 vs. 44.8, P=0.003). In the HR⁺ subgroup, the 9-year recurrence-free survival (RFS) was significantly higher in HER2-low BC than in HER2-zero BC [77.8% vs. 53.5%; hazard ratio =0.3026; 95% confidence interval (CI): 0.1039-0.8817; P=0.03]. HR⁺ DR low-risk BC patients without adjuvant chemotherapy had better 9-year RFS (100% vs. 99.7%, P=0.60) and overall survival (OS) (100% vs. 99.7%, P=0.60) than those who received chemotherapy.

Our results demonstrated that HER2-zero group have a higher recurrence risk and poor prognosis than HER2-low group. HER2-low HR⁺ RecurIndex-DR low risk patients may not benefit from adjuvant chemotherapy. RecurIndex may help explore prognostic stratification and may guide potential chemotherapy de-escalation in HER2-low early BC, laying groundwork for future ADC use.